Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.
Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.